-
1.发明授权Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents 有权磺酰亚胺取代的嘧啶作为CDK和/或VEGF抑制剂，其生产和用作药剂公开(公告)号：US07338958B2
公开(公告)日：2008-03-04
申请号：US10966098
申请日：2004-10-18
IPC分类号： A61K31/506 , C07D239/34 , C07D239/38 , C07D239/48 , A61P35/00 , C07D239/30 , C07D239/56 , C07C315/04 , C07C317/14 , C07C307/02 , C07C311/07
CPC分类号： C07D239/47 , C07D239/48
摘要： This invention relates to pyrimidine derivatives of general formula I in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
摘要翻译： 本发明涉及通式I的嘧啶衍生物，其中Q，R 1，R 2，R 3，R 4， R 5，X 5和m具有说明书中所含的含义，作为细胞周期蛋白依赖性激酶和VEGF-受体酪氨酸激酶的抑制剂，其生产及其用途 用于治疗各种疾病的药物。
-
2.发明申请Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents 有权磺酰亚胺取代的嘧啶作为CDK和/或VEGF抑制剂，其生产和用作药剂公开(公告)号：US20050176743A1
公开(公告)日：2005-08-11
申请号：US10966098
申请日：2004-10-18
IPC分类号： A61K31/506 , A61K31/513 , C07D239/46 , C07D239/48 , C07D43/02
CPC分类号： C07D239/47 , C07D239/48
摘要： This invention relates to pyrimidine derivatives of general formula I in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
摘要翻译： 本发明涉及通式I的嘧啶衍生物，其中Q，R 1，R 2，R 3，R 4， R 5，X 5和m具有说明书中所含的含义，作为细胞周期蛋白依赖性激酶和VEGF-受体酪氨酸激酶的抑制剂，其生产及其用途 用于治疗各种疾病的药物。
-
公开(公告)号：US20080167330A1
公开(公告)日：2008-07-10
申请号：US11892967
申请日：2007-08-28
IPC分类号： A61K31/505 , C07D239/48 , C07D239/47 , C07D409/04 , A61P35/00 , C07D239/42 , C07D239/34 , C07D403/02 , A61K31/513 , A61K31/506
CPC分类号： C07D239/47 , C07D239/48 , C07D403/12
摘要： The invention relates to carbamoylsulphoximides as protein kinase inhibitors of the general formula 1.
摘要翻译： 本发明涉及作为通式1的蛋白激酶抑制剂的氨基甲酰基亚砜。
-
公开(公告)号：US07943629B2
公开(公告)日：2011-05-17
申请号：US11759479
申请日：2007-06-07
申请人： Ulrich Luecking , Duy Nguyen , Arne von Bonin , Oliver von Ahsen , Gerhard Siemeister , Rolf Jautelat , Wolf-Dietrich Doecke
发明人： Ulrich Luecking , Duy Nguyen , Arne von Bonin , Oliver von Ahsen , Gerhard Siemeister , Rolf Jautelat , Wolf-Dietrich Doecke
IPC分类号： C07D239/48 , A61K31/506
CPC分类号： C07D401/12 , C07D239/48
摘要： The invention relates to sulphimides as protein kinase inhibitors of the general formula I
摘要翻译： 本发明涉及作为通式I的蛋白激酶抑制剂的硫酰亚胺
-
5.发明申请NOVEL HETARYL-PHENYLENEDIAMINE-PYRIMIDINES AS PROTEIN KINASE INHIBITORS 审中-公开作为蛋白激酶抑制剂的新型食品 - 苯二胺 - 嘧啶公开(公告)号：US20080176866A1
公开(公告)日：2008-07-24
申请号：US11960118
申请日：2007-12-19
IPC分类号： A61K31/495 , C07D239/28 , A61P35/00
CPC分类号： C07D239/48 , C07D239/47 , C07D401/12 , C07D403/12 , C07D403/14 , C07D405/14 , C07D417/12
摘要： The invention relates to novel hetaryl-phenylenediamine-pyrimidines and to their structurally related oxygen and sulphur analogues of the general formula I, processes for their preparation, and their use as medicaments.
摘要翻译： 本发明涉及新型的杂芳基 - 苯二胺 - 嘧啶及其结构相关的通式I的氧和硫类似物，其制备方法及其作为药物的用途。
-
公开(公告)号：US20080058358A1
公开(公告)日：2008-03-06
申请号：US11759479
申请日：2007-06-07
申请人： Ulrich Luecking , Duy Nguyen , Arne von Bonin , Oliver von Ahsen , Gerhard Siemeister , Rolf Jautelat , Wolf-Dietrich Doecke
发明人： Ulrich Luecking , Duy Nguyen , Arne von Bonin , Oliver von Ahsen , Gerhard Siemeister , Rolf Jautelat , Wolf-Dietrich Doecke
IPC分类号： A61K31/505 , A61K31/506 , A61P35/00 , C07D239/30 , C07D239/48 , C07D401/12
CPC分类号： C07D401/12 , C07D239/48
摘要： The invention relates to sulphimides as protein kinase inhibitors of the general formula I
摘要翻译： 本发明涉及作为通式I的蛋白激酶抑制剂的硫酰亚胺
-
7.发明申请N-aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents 失效N-芳基 - 亚磺酰亚胺取代的嘧啶作为CDK和/或VEGF抑制剂，它们的生产和用作药剂公开(公告)号：US20060229325A1
公开(公告)日：2006-10-12
申请号：US11386111
申请日：2006-03-22
IPC分类号： A61K31/513 , A61K31/506 , C07D417/02
CPC分类号： C07D239/48 , C07D239/47 , C07D239/50 , C07D333/48 , C07D401/12 , C07D405/12 , C07D409/12
摘要： This invention relates to pyrimidine derivatives of general formula (I) in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
摘要翻译： 本发明涉及通式（I）的嘧啶衍生物，其中Q，R 1，R 2，R 3，R 4，R 5，X和m具有本说明书所含的含义，作为细胞周期蛋白依赖性激酶和VEGF- 受体酪氨酸激酶，它们的生产以及它们作为用于治疗各种疾病的药物的用途。
-
8.发明授权N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents 失效作为CDK和/或VEGF抑制剂的N-芳基 - 亚磺酰亚胺取代的嘧啶，它们的生产和用作药剂公开(公告)号：US07456191B2
公开(公告)日：2008-11-25
申请号：US11386111
申请日：2006-03-22
IPC分类号： A01N43/54 , A61K31/505 , C07D239/02
CPC分类号： C07D239/48 , C07D239/47 , C07D239/50 , C07D333/48 , C07D401/12 , C07D405/12 , C07D409/12
摘要： This invention relates to pyrimidine derivatives of general formula (I) in which Q, R1, R2, R3, R4, R5, X, and m have the meanings that are contained in the description, as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases, their production as well as their use as medications for treatment of various diseases.
摘要翻译： 本发明涉及通式（I）的嘧啶衍生物，其中Q，R 1，R 2，R 3，R 4，R 5，X和m具有本说明书所含的含义，作为细胞周期蛋白依赖性激酶和VEGF- 受体酪氨酸激酶，它们的生产以及它们作为用于治疗各种疾病的药物的用途。
-
公开(公告)号：US07312225B2
公开(公告)日：2007-12-25
申请号：US10644076
申请日：2003-08-20
IPC分类号： A61P35/00 , A61K31/505 , C07D245/00
CPC分类号： C07D239/42 , C07D239/48 , C07D409/12 , C07D487/08 , C07D513/08
摘要： Macrocyclic pyrimidine derivatives of general formula I in which R1 to R5, X, Y, A, B, m and n have the meanings that are contained in the description, as inhibitors of the cyclin-dependent kinase, their processes for production as well as their use as medications for treating various diseases are described.
摘要翻译： R 1至R 5，X，Y，A，B，m和n的通式I的大环嘧啶衍生物具有说明书中所含的含义， 作为细胞周期蛋白依赖性激酶的抑制剂，其生产方法以及它们作为用于治疗各种疾病的药物的用途。
-
公开(公告)号：US08524724B2
公开(公告)日：2013-09-03
申请号：US12142279
申请日：2008-06-19
申请人： Ingo Hartung , Ulrich Bothe , Georg Kettschau , Ulrich Luecking , Anne Mengel , Martin Krueger , Karl Thierauch , Philip Lienau , Ulf Boemer
发明人： Ingo Hartung , Ulrich Bothe , Georg Kettschau , Ulrich Luecking , Anne Mengel , Martin Krueger , Karl Thierauch , Philip Lienau , Ulf Boemer
IPC分类号： A01N43/54 , A61K31/505 , C07D401/00 , C07D403/00 , C07D405/00 , C07D409/00 , C07D411/00 , C07D413/00 , C07D417/00 , C07D419/00 , C07D239/02
摘要： The invention relates to alkynylpyrimidines according to the general formula (I): in which A, R1, R2, R3, R4, R5, and R6 are as defined in the claims, and salts, N-oxides, metabolites, solvates, tautomers and prodrugs thereof, to pharmaceutical compositions comprising said alkynylpyrimidines, to methods of preparing said alkynylpyrimidines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 and VEGFR2 signalling.
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.025 秒)
